Company: HROW
Filing Date: 2025-03-27
Form Type: 10-K
Source: 0001641172-25-000925
Chunk: 17

Company: HARROW, INC.
Filing Date: 2025-03-27
Form: 10-K
Item: Item 1
Chunk 17
---
 1, 2025, we owned and/or licensed more than
50 total issued and pending patent applications, which include U.S.-issued patents, international-issued patents, and U.S. and foreign/international
patent pending applications. We expect to file additional patent applications in the U.S. and pursue patent protection for certain of
our formulations in other important international jurisdictions in the future.

As of March 1, 2025, we had,
on a worldwide basis, more than 100 issued trademarks, pending trademark and copyright applications, or registered copyrights and/or
trademarks. We also rely on unpatented trade secrets and know-how and continuing technological innovation in order to develop our products
and formulations, which we seek to protect, in part, by confidentiality agreements with our employees, consultants, collaborators and
others, including certain service providers. We also have invention or patent assignment agreements with our current employees and certain
consultants. However, our employees and consultants may breach these agreements, and we may not have adequate remedies for any breach,
or our trade secrets may otherwise become known or be independently discovered by competitors. In addition, inventions relevant to us
could be developed by a person not bound by an invention assignment agreement with us, in which case we may have no rights to use the
applicable invention.

The
following table lists our outstanding material patents in the U.S. for certain branded products, general subject matter and latest expiry
date. One or more patents with the same or earlier expiry dates may fall under the same general subject matter and are not listed separately.

    Product
     
    General Subject Matter
     
    Expiration
  
    IHEEZO
     
    Methods using topical formulations
    Compositions compromising chloroprocaine
     
    September 2038
    May 2039
  
    VEVYE
     
    Formulation composition for treatment of dry
    eye syndrome
    Ophthalmic composition comprising cyclosporine
    Semiflourinated compounds for ophthalmic administration
    Topical administration method
     
    December 2030
    September 2037
    November 2038
    October 2039
  
    TRIESENCE
     
    Composition of injectable suspension
    Methods for treating ophthalmic disorder
     
    December 2029
    March 2029
  
    ILEVRO
     
    Composition comprising carbomer, galactomannan and borate